Navigation Links
Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
Date:4/21/2008

COMPANY WILL INITIATE COMMERCIAL LAUNCH PROGRAM TO ADD NEW CENTERS AND TO

INCREASE AWARENESS AMONG CARDIOLOGISTS

PLEASANTON, Calif., April 21 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it has received FDA approval of its PMA (PreMarket Approval) application, allowing the use of its HeartMate II LVAS (Left Ventricular Assist System) as a bridge-to-transplantation (BTT) in patients suffering from advanced-stage heart failure.

The approval follows a successful clinical trial involving more than 450 BTT patients, including those enrolled under Continued Access Protocols, and a unanimous recommendation for approval from the FDA Circulatory System Devices Advisory Panel last November.

"The HeartMate II is the first continuous flow device to receive FDA approval for this intended use in the U.S., representing a milestone in the treatment of advanced-stage heart failure patients and for the clinicians who treat them," said Gary F. Burbach, president and chief executive officer of Thoratec. "As our clinical trial indicated, the HeartMate II represents a new era in the treatment of advanced-stage heart failure with data demonstrating excellent survival rates, quality of life and functional capacity for a broad range of patients. This patient experience has created a high level of enthusiasm for the HeartMate II within the clinical community. We are hopeful that the device's trial experience, ease of implantation, small size and ability to provide longer duration support will result in broader adoption of mechanical circulatory support for the treatment of thes
'/>"/>

SOURCE Thoratec Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
2. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
3. Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
4. InterMune Announces Progress on Pirfenidone in IPF
5. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
6. Aida Announces New Anti-Cancer Drug Under Development
7. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
8. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
10. ViroPharma Announces Discontinuation of HCV-796 Development
11. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015  Hologic, Inc. (NASDAQ: ... cancer screening study i published on-line this ... journal of the American Cancer Society. ... the University of Pittsburgh Medical Center, supports current consensus guidelines ... that women 30-65 years of age be co-tested ...
(Date:4/16/2015)... April 16, 2015 Mallinckrodt plc (NYSE: ... today announced that it has completed its acquisition ... approximately $2.3 billion. The Ikaria acquisition extends Mallinckrodt,s ... reach into neonatal critical care with INOMAX ® ... for a highly vulnerable patient population. It also ...
(Date:4/16/2015)... , April 16, 2015  Rosewind Corporation (OTCMKTS: ... reverse merger with a newly formed specialty healthcare ... focus on addressing urological disorders. The merged company, ... Inc., has commenced operations and incorporates the pipeline ... The Company,s strategy is to build a late-stage ...
Breaking Medicine Technology:Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 2Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 3Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 4Mallinckrodt Completes Acquisition Of Ikaria 2Mallinckrodt Completes Acquisition Of Ikaria 3Mallinckrodt Completes Acquisition Of Ikaria 4Mallinckrodt Completes Acquisition Of Ikaria 5Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 2Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 3
... Fla., May 26, 2011 Tigris Pharmaceuticals, Inc., today ... Phase 2 clinical trial of AFP-464 (aminoflavone prodrug) with ... cancer patients. Molecular profiling will be used to pre-screen ... which has shown to predict sensitivity to ...
... 26, 2011 Medical Affairs serves as the linchpin for ... a successful market entry of a new product. ... trial strategy & planning, and publication strategy & planning, are ... the activities where organizations turn to Medical Affairs to play ...
Cached Medicine Technology:Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients 2Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients 3Medical Affairs Role in New Product Planning Detailed in Best Practices, LLC Report 2
(Date:4/18/2015)... “ ArcAngel ” was featured on NewsWatch as part of ... and coolest applications on the market for iOS, ... technology expert, conducted the app review and shared with viewers ... a turbulent world, people may find themselves in dangerous situations ... first move, but some situations can be avoided if there ...
(Date:4/17/2015)... Rosetta Radiology is proud to now offer ... of diagnostic imaging services. This solidifies them as a ... East Side of Manhattan. , The new imaging equipment ... of PET-CT, combined with Rosetta’s state of the art ... with patients through several stages of the cancer care ...
(Date:4/17/2015)... have seen healing, a lot of healing, and a lot ... Kafader of Friendship Village. “People have found purpose. ... have created beautiful pieces of art.” For the past eight ... was launched to benefit residents of the retirement community. , ... Institute in Chicago, worked as an intern at Friendship Village, ...
(Date:4/17/2015)... Rapids, MI (PRWEB) April 17, 2015 Enthusiasts ... CRUSH Grand Rapids, Saturday, April 25, 2015. The event will ... Reserve Wine & Food (201 Monroe Ave NW, Grand Rapids, ... from around the West Michigan area. Patrons are encouraged to ... of elegance and fun. , This year’s event will feature ...
(Date:4/17/2015)... Baptist Health and The University of Texas ... designed to transform oncology care in northeast Florida and ... create a joint cancer program to enhance patient access ... MD Anderson Cancer Center is anticipated to open in ... highly coordinated, multidisciplinary cancer care for adults in the ...
Breaking Medicine News(10 mins):Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:Healing At Friendship Village Due To Art Therapy 2Health News:Children’s Leukemia Foundation of Michigan Presents 3rd Annual CRUSH Grand Rapids 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3
... up nationwide installation service for its smartTOUCH(R),product line, ... (OTC,Bulletin Board: BMRX) today announced that it has ... national handyman service, Mr.,Handyman, to provide its customers ... products that,include garage door openers, door locks, thermostats, ...
... Non-systemic and Non-invasive Treatment Cleared for,Patients Who Have ... Pa., Oct. 8 Neuronetics, Inc., a,privately-held medical ... of,neuromodulation, announced today that the U.S. Food and ... Magnetic Stimulation),Therapy system for the treatment of depression. ...
... 8 ILC Dover (http://www.ilcdover.com ),the company ... a premium line of aesthetically pleasing head covers ... product is the direct result,of feedback from healthcare ... less intimidating and more "patient friendly"., (Photo: ...
... ,Tis the season to be jolly, but all,the money ... have you,feeling less than merry. Don,t let yourself fall ... sense of obligation. Take the following,simple measures to prevent ... Family Therapists (CAMFT) http://www.camft.org :, -- Make ...
... Canadian Annual Meeting (November 5-7; Ottawa, Ontario, Canada) to ... the pharmaceutical industry, health academia, and the health care ... ... Horsham, PA (PRWEB) October 8, 2008 -- The http://www.diahome.org/ ...
... extension of its existing strategic alliance with Nano-Terra, Inc., a leading ... ... Wire EON) October 7, 2008 -- The original agreement between ... products and solutions based on Merck,s materials. , , , After ...
Cached Medicine News:Health News:bioMETRX Teams Up With Mr. Handyman 2Health News:bioMETRX Teams Up With Mr. Handyman 3Health News:FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression 2Health News:FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression 3Health News:FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression 4Health News:FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression 5Health News:ILC Dover Introduces 'Patient Friendly' Respiratory Protection for Health Care Market 2Health News:Holiday Gift Giving: How You and Your Budget can Survive the Season 2Health News:DIA 6th Canadian Annual Meeting Benefit and Risk Management: An Evolution in Progress 2Health News: Merck KGaA and Nano-Terra Announce Extension of Nanotechnology Solutions Alliance 2Health News: Merck KGaA and Nano-Terra Announce Extension of Nanotechnology Solutions Alliance 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: